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Therapeutically targeting 
mitochondrial redox signalling 
alleviates endothelial dysfunction 
in preeclampsia
Cathal McCarthy & Louise C. Kenny
Aberrant placentation generating placental oxidative stress is proposed to play a critical role in 
the pathophysiology of preeclampsia. Unfortunately, therapeutic trials of antioxidants have been 
uniformly disappointing. There is provisional evidence implicating mitochondrial dysfunction as a 
source of oxidative stress in preeclampsia. Here we provide evidence that mitochondrial reactive 
oxygen species mediates endothelial dysfunction and establish that directly targeting mitochondrial 
scavenging may provide a protective role. Human umbilical vein endothelial cells exposed to 3% 
plasma from women with pregnancies complicated by preeclampsia resulted in a significant decrease in 
mitochondrial function with a subsequent significant increase in mitochondrial superoxide generation 
compared to cells exposed to plasma from women with uncomplicated pregnancies. Real-time PCR 
analysis showed increased expression of inflammatory markers TNF-α, TLR-9 and ICAM-1 respectively 
in endothelial cells treated with preeclampsia plasma. MitoTempo is a mitochondrial-targeted 
antioxidant, pre-treatment of cells with MitoTempo protected against hydrogen peroxide-induced 
cell death. Furthermore MitoTempo significantly reduced mitochondrial superoxide production in cells 
exposed to preeclampsia plasma by normalising mitochondrial metabolism. MitoTempo significantly 
altered the inflammatory profile of plasma treated cells. These novel data support a functional role 
for mitochondrial redox signaling in modulating the pathogenesis of preeclampsia and identifies 
mitochondrial-targeted antioxidants as potential therapeutic candidates.
Preeclampsia is a pregnancy-specific syndrome that complicates 5% of nulliparous pregnancies and worldwide 
affects approximately 4 million women per annum1. Globally, preeclampsia is a leading cause of maternal mortal-
ity and it is responsible for occupancy of approximately 20% of neonatal intensive care unit cots. The syndrome is 
characterized clinically by maternal hypertension accompanied by proteinuria or haematological or biochemical 
abnormalities1. Despite intense research, the precise pathophysiological mechanisms underlying this syndrome 
remain poorly elucidated.
However, there is substantial evidence that defective placentation in early pregnancy is a pivotal event in the 
aetiology of this condition2. A consequential reduction in placental perfusion provokes an ischemic placental 
microenvironment due to fluctuations in oxygen delivery to the placenta and fetus, which results in oxidative 
stress3. Elevated placental oxidative stress is evident in preeclampsia as early as ~8–10 weeks’ gestation4. Placental 
ischemia is inherently linked to elevated production and secretion of placental-derived deleterious mediators 
that induce widespread maternal endothelial dysfunction. Uncomplicated pregnancy is itself a state of oxida-
tive stress5 as a result of amplified maternal metabolism and the subsequent metabolic activity of the placenta6. 
However, during preeclampsia the mitigative systems normalizing the placental oxidative state are distorted, 
leading to elevated generation of pathogenic factors and subsequent vascular dysfunction. During preeclampsia, 
oxidative stress manifests in both the placenta and maternal circulation7, with evidence of diminished antioxidant 
defences8, increased free radical formation and isoprostanes9.
There are several sources of reactive oxygen species (ROS) within the cell; however mitochondria are the 
dominant cellular producers of ROS. Recent evidence has established that mitochondrial-ROS (mROS) have 
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evolved as raconteurs directing mitochondrial function and other critical physiological signalling roles to 
preserve homeostasis and stimulate adaption to deleterious stressors10. There is a growing body of evidence 
implicating mitochondrial dysfunction as a pathogenic mediator of oxidative stress in preeclampsia11. There 
is substantial mitochondrial content in the placenta, in part to mediate the elevated metabolic activities dur-
ing pregnancy12. Excessive production of mitochondrial-ROS is intrinsically linked to mitochondrial dysfunc-
tion13,14. Furthermore, there is a higher incidence of preeclampsia in a family with pre-diagnosed mitochondrial 
dysfunction15.
MitoTempo is a mitochondria-targeted superoxide dismutase antioxidant mimetic. Recent work demon-
strated that MitoTempo accumulates in the mitochondria by increasing mitochondrial O2−dismutation while not 
affecting cytoplasmic dismutation in endothelial cells16. Additionally, MitoTempo decreased mitochondrial O2−in 
intact endothelial cells. Furthermore, MitoTempo improved endothelial function and reduced mROS production 
in an in vivo model of hypertension16. In the current studies, we identified that deleterious plasma mediators 
present in preeclampsia generate increased mitochondrial-specific superoxide production, by treating HUVEC 
with pooled plasma from preeclampsia pregnancies and matched uncomplicated controls from the SCOPE study 
(www.scopestudy.net) and non-pregnant controls. We show that increased mROS production evoked vascular 
dysfunction. Finally, we determine that antioxidants (MitoTempo) directly targeting mitochondrial superoxide 
scavenging prevent increased mROS production and elucidate the potential novel therapeutic pathway that may 
treat the syndrome more effectively.
Results
Preeclampsia plasma mediators modulate mitochondrial metabolism in HUVEC. The emerging 
role of mitochondrial dysfunction in mediating the pathogenesis of preeclampsia, led us to investigate a potential 
link between deleterious plasma mediators in preeclampsia and a subsequent dysregulation of mitochondrial 
function in HUVEC. In our first set of experiments we examined mitochondrial respiration by measuring oxy-
gen consumption in plasma-treated HUVEC using the MitoXpress assay containing an oxygen sensitive fluo-
rescent probe. Rates of oxygen consumption (OCR) are calculated from the changes in fluorescence signal over 
time using fluorescence plate reader. We established that after 4 hrs incubation of HUVEC with 3% plasma from 
women with preeclampsia significantly reduced OCR (40.61 ± 18.10 RFU, n = 5, P < 0.05) when compared with 
treatment with 3% plasma from uncomplicated pregnant (94.12 ± 34.9 RFU, n = 5) and non-pregnant women 
(52.12 ± 18.8, n = 5) (Fig. 1).
Preeclampsia plasma mediators alter PGC-1α expression in HUVEC. Given that peroxisome 
proliferator activated receptor γ co-activator 1-α (PGC-1α ) mediates mitochondrial biogenesis and antioxi-
dant activity in HUVEC; we determined the effect of preeclampsia plasma on protein expression of PGC-1α in 
HUVEC. Preeclampsia plasma stimulated a significant increase in PGC-1α protein expression (140.63% ± 13.5%, 
n = 5, P < 0.05) when compared with treatment with 3% plasma from uncomplicated pregnant (101.08% ± 3.97%, 
n = 5) and non-pregnant women (100% ± 0%, n = 5) (Fig. 2a). Additionally, we measured the effect of preec-
lampsia plasma on mitochondrial mass in treated HUVEC using MitoID Green by fluorescent microscopy. This 
fluorogenic reagent preferentially accumulates in mitochondria becoming fluorescent in their lipid environment. 
There was no significant difference in mitochondrial mass (89% ± 8.63, n = 3) when compared with treatment 
with 3% plasma from uncomplicated pregnant (94.91% ± 9.46%, n = 3) and non-pregnant women (100% ± 0%, 
n = 3) (Fig. 2b,c).
Figure 1. Preeclampsia plasma alters mitochondrial metabolism in plasma treated HUVEC. (a) Human 
umbilical vein endothelial cells were incubated with 3% plasma from women with preeclampsia, uncomplicated 
pregnancies and non-pregnant women for 4 hrs. Oxygen consumption rate was measured with MitoXpress 
fluorogenic probe. Time-resolved fluorescence of each well was then measured every 2 minutes for a total of 180 
minutes. Rate of oxygen consumption was determined from the slope of fluorescence vs. time for each sample 
using relative fluorescence units/hour. Data are expressed as mean ± SEM. (*P < 0.05 vs normal pregnancy). 
Data are representative of 5 independent experiments.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:32683 | DOI: 10.1038/srep32683
Preeclampsia plasma increases mitochondrial-specific ROS generation in HUVEC. Excessive 
production of mitochondrial-ROS is intrinsically linked to mitochondrial dysfunction. To measure 
mitochondrial-specific superoxide production, plasma-treated cells were labelled with MitoSox Red dye and 
measured by fluorescent microscopy. Therefore, in our next set of experiments (Fig. 3a,b), we observed that treat-
ment of HUVEC with 3% plasma from women with preeclampsia significantly increased mitochondrial-specific 
superoxide generation (191.82% ± 25%, n = 10, P <  0.05) when compared with treatment with 3% plasma from 
uncomplicated pregnant (127.65% ± 24%, n = 10) and non-pregnant women (100% ± 0%, n = 10) (Fig. 3b).
Effect of preeclampsia-plasma mediators on endogenous endothelial antioxidant and inflam-
matory markers. Given the proficiency of mROS in regulating various signalling pathways and consequent 
pathologies, the effect of plasma mediators on antioxidant gene expression was determined by quantitative 
real-time PCR in HUVEC. Incubation with preeclampsia plasma induced a significant increase in SOD1 gene 
expression (1.32 ± 0.10 fold, n = 8, P < 0.05), SOD2 gene expression (1.35 ± 0.21 fold, n = 8, P < 0.05) and HO-1 
gene expression (1.82 ± 0.42 fold, n = 8, P < 0.05) respectively compared to uncomplicated pregnancy (Fig. 4a).
Mitochondrial damage associated molecular patterns (DAMPs) including mtDNA are ligands for TLR-
9-induced inflammation14,17. The levels of mtDNA relative to nuclear DNA were measured in plasma from preec-
lampsia and uncomplicated pregnancies respectively. Preeclampsia plasma had a significant increase in mtDNA 
(5.49 ± 0.33 fold, n = 12, P < 0.01) compared to plasma from uncomplicated pregnancy (Fig. 4b). Subsequently, 
preeclampsia plasma mediators significantly increased enodthelial TLR-9 gene expression (1.43 ± 0.17 fold, n = 8, 
P < 0.01) and pro-inflammatory TNF-α gene expression (2.65 ± 0.17 fold, n = 8, P < 0.01) in HUVEC respec-
tively, compared to uncomplicated pregnancy. Additionally, preeclamspia plasma mediators increased endothe-
lial dysfunction as evident from the significant increase in gene expression of ICAM-1 (3.92 ± 0.51 fold, n = 8, 
P < 0.01) in HUVEC respectively, compared to uncomplicated pregnancy (Fig. 4c).
Cytoprotective effects of MitoTempo on H2O2-induced cell death. The aim of the next series of 
experiments was to analyse the protective properties of mitochondrial targeted antioxidant, MitoTempo in 
HUVEC in response to cellular stressors. Initially we determined the optimal concentration of MitoTempo that 
did not adversely affect cell viability. HUVEC were treated with increasing concentrations of MitoTempo and 
cell viability was determined using an MTT assay. In summary, 5 uM MitoTempo was used in subsequent exper-
iments (Fig. 5a). Additionally, using an MTT assay we determined that 5 uM of non-mitochondrial targeted 
Figure 2. Determination of mitochondrial biogenesis/mass in plasma treated HUVEC. (a) PGC-1α protein 
expression was detected by fluorescent microscopy and quantified using Image J software. Data is the mean 
of 5 independent experiments and are expressed as difference in percentage pixel intensity between the study 
groups ± SEM. *P < 0.05. (b) Mitochondrial mass was determined using fluorogenic MitoID Green reagent. 
Confocal microscopy of MitoID Green (green fluorescence, 1st panel) and Hoechst 33342 (blue fluorescence, 
2nd panel) at 20X. Merged image localizes mitochondria (3rd panel). (c) Mitochondrial mass (MitoID Green 
intensity) was quantified using Image J software. Data is the mean of 3 independent experiments and are 
expressed as difference in percentage pixel intensity between the study groups.
www.nature.com/scientificreports/
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N-acetylcysteine (NAC) was the optimal concentration that did not adversely affect HUVEC cell viability 
(Fig. 5b).
Furthermore, H2O2 is frequently used as a cellular stressor to mimic oxidative stress in in vitro cellular systems 
and is a potential pathogenic mediator present in the preeclampsia plasma milieu. To determine the optimal dose 
of H2O2 that reduces cell viability in HUVEC, cells were treated with increasing concentrations of H2O2 and cell 
viability was recorded by MTT assay. A significant reduction in cell viability was seen in cells treated with a range 
of 20 uM-500 uM H2O2 compared to control (*P < 0.05 and **P < 0.01). 200 uM H2O2 was chosen as the optimal 
dose to use in subsequent experiments as it significantly reduced HUVEC cell viability by approximately 35% 
(Fig. 5c).
Having determined that treatment of HUVEC with 200 uM H2O2 significantly reduced cell viability, we sought 
to establish if pre-treating cells with 5 uM MitoTempo could neutralize these destructive effects. Pre-treatment 
with 5 uM MitoTempo rescued H2O2-induced cell death (87.23% ± 1.51% vs 75.32% ± 2.68%, n = 5, P < 0.05) 
establishing the therapeutic capacity of mitochondrial-targeted antioxidants in reducing H2O2 cytotoxicity 
(Fig. 5d).
MitoTempo reduces preeclampsia plasma mediated increase in mitochondrial-specific ROS 
generation in HUVEC. We examined if pre-incubation with MitoTempo could scavenge the volume 
Figure 3. Detection of mitochondrial-specific superoxide in plasma treated HUVEC. HUVEC were 
incubated with 3% plasma from women with preeclampsia, uncomplicated pregnancies and non-pregnant 
women for 4 hrs and mitochondrial-specific superoxide was detected using fluorogenic MitoSox Red dye.  
(a) Confocal microscopy of MitoSox (red fluorescence, 1st panel) and DAPI (blue fluorescence, 2nd panel) at 
20X. Merged image localizes mitochondrial superoxide production (3rd panel). (b) MitoSox Red generation 
was quantified using Image J software. Data is the mean of 10 independent experiments and are expressed as 
difference in percentage pixel intensity between the study groups ± SEM. **P < 0.01.
www.nature.com/scientificreports/
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of mROS production in HUVEC exposed to preeclampsia plasma mediators. To elucidate the proficiency of 
mitochondrial-specific antioxidants, we additionally included non-mitochondrial targeted N-acetylcysteine 
(NAC) in our next experiments. Cells were pre-treated with 5 μ M MitoTempo or 5 μ M NAC for 2 hrs prior to 
exposure to 3% plasma from women with preeclampsia and levels of mitochondrial superoxide were detected 
by fluorogenic MitoSox Red dye and analysed using Image J software. Pre-treatment with MitoTempo signifi-
cantly reduced mROS generation compared to untreated cells (61.23% ± 15.42% vs 100% ± 0%, n = 9, P < 0.01). 
Pre-treatment with non-targeted antioxidants reduced mROS production (79.73% ± 13.97% vs 100% ± 0%, n = 9, 
P < 0.05) but its effects are not as potent as targeted mitochondrial antioxidants (Fig. 6).
MitoTempo mediates redox and inflammatory signals in response to cellular stressors. To 
specifically elucidate the protective effects of mitochondrial targeted antioxidant, MitoTempo in regulating 
pathogenic cellular pathways in endothelial cells, HUVEC were pre-treated with MitoTempo prior to exposure 
to stressors including H2O2 (oxidative stress) and LPS (inflammation). Firstly, we examined the expression of 
inflammatory markers in response to 24 hrs stimulation with LPS (100 ng/ml) with/without 2 hrs MitoTempo (5 μ 
M) pre-treatment. There was a significant decrease in TNF-α gene expression (2.09 ± 0.18 fold vs 0.99 ± 0.15 fold, 
n = 3, P < 0.01) (Fig. 7a) in cells pretreated with MitoTempo compared to untreated cells.
Additionally, we determined the expression of redox signalling markers in response to 24 hrs stimulation 
with H2O2 (200 μ M) with/without 2 hrs MitoTempo (5 μ M) pre-treatment. There was a significant decrease in 
UCP-1 gene expression (12.23 ± 0.39 fold vs 0.95 ± 0.43 fold, n = 3, P < 0.01) in cells pretreated with MitoTempo 
compared to untreated cells. Uncoupling proteins mediate the electrochemical potential across the inner mito-
chondrial membrane, which can subsequently regulate mROS production. Furthermore, there was a significant 
decrease in TLR-9 gene expression (4.2 ± 0.73 fold vs 1.02 ± 0.19 fold, n = 3, P < 0.05), demonstrating a novel role 
for MitoTempo in reducing mROS-mediated innate immune response (Fig. 7b).
Discussion
In excess of 800 peer-reviewed publications over the past 25 years have corroborated the hypothesis that oxi-
dative damage is involved in the pathophysiology of preeclampsia yet current antioxidant interventions are not 
Figure 4. Preeclampsia plasma alters endothelial antioxidant and inflammatory profiles. HUVEC were 
incubated with 3% plasma from women with preeclampsia and uncomplicated pregnancies for 24 hrs and gene 
expression of antioxidant and inflammatory markers were quantified by real-time PCR. (a) Gene expression 
of redox signalling mediators, SOD1, SOD2, HO-1 and UCP-1 respectively was determined in plasma-
treated HUVEC. The amounts of amplified products are expressed relative to geometric mean of two internal 
controls. Data are representative of 8 independent experiments. (b) Real-time PCR quantifying the levels of 
mtDNA relative to nuclear DNA in plasma from preeclampsia and uncomplicated pregnancies respectively. 
Data are mean fold change compared to uncomplicated pregnancy ± SEM. **P < 0.01. Data are representative 
of 12 independent experiments. (c) Gene expression of inflammatory markers TNF-α , TLR-9 and ICAM-1 
respectively was determined in plasma-treated HUVEC. The amounts of amplified products are expressed 
relative to geometric mean of two internal controls. Data are representative of 8 independent experiments. Data 
are mean fold change compared to uncomplicated pregnancy ± SEM. *P < 0.05; **P < 0.01.
www.nature.com/scientificreports/
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clinically effective. One possible explanation is that these antioxidant regimens have failed to reach the intracel-
lular location, namely the mitochondria; hence they have failed to ameliorate the pathological oxidative damage. 
Figure 5. MitoTempo reduces H2O2 mediated cell death. (a) Dose dependent effect of MitoTempo on 
HUVEC cell viability was assessed using a MTT assay. HUVEC were treated with varying concentrations 
of MitoTempo for 24 hrs. Data are expressed as mean ± SEM. (*P < 0.05; **P < 0.01 vs control). Data are 
representative of 5 independent experiments. (b) Dose dependent effect of NAC on HUVEC cell viability 
was assessed using a MTT assay. HUVEC were treated with varying concentrations of NAC for 24 hrs. Data 
are expressed as mean ± SEM. (*P < 0.05; **P < 0.01 vs control). Data are representative of 3 independent 
experiments. (c) Dose dependent effect of H2O2 on HUVEC cell viability was assessed using an MTT assay. 
HUVEC were treated with increasing concentrations of H2O2 for 24 hours. Data are expressed as mean ± SEM. 
(*P  <  0.05; **P < 0.01 vs control). Data are representative of 5 independent experiments. (d) MitoTempo is 
protective of H2O2-induced cell death in HUVEC. Cells were pre-treated for 2 hrs with 5 μ M MitoTempo and 
subsequently exposed to 200 μ M H2O2 for 24 hrs, cell viability was assessed by MTT assay. Data are expressed 
as mean ± SEM. (*P < 0.05; vs control). Data are representative of 5 independent experiments.
Figure 6. MitoTempo scavenging reduces mROS production. HUVEC were pre-treated with 5 μ M 
MitoTempo or 5 μ M NAC for 2 hrs prior to incubation with 3% plasma from women with preeclampsia for 4 hrs 
and mitochondrial-specific superoxide production was detected using fluorogenic MitoSox Red dye. MitoSox 
Red generation was quantified using Image J software. Data is the mean of 9 independent experiments and are 
expressed as difference in percentage pixel intensity compared to untreated ± SEM, *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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Mitochondrial pharmacology has recently greatly advanced with a number of different pharmacology strategies 
in development to address mitochondrial dysfunction.
Mitochondrial dysfunction is a pathogenic mediator of oxidative stress in preeclampsia with increased mito-
chondrial lipid peroxidation and enhanced susceptibility to oxidation evident in mitochondria in the placenta 
of pregnancies complicated by preeclampsia18. Endothelial cells are the primary targets of the circulating factors 
and preeclampsia is characterised by aberrant vascular dysfunction19. There are a number of different instiga-
tors that distort mitochondrial function, including altered oxygen consumption, decreased ATP production, 
increased mROS production and mtDNA damage20. We explored the pathogenic mechanisms of preeclampsia 
plasma mediators on mitochondrial function by assessing oxygen consumption rates. We showed that preeclamp-
sia plasma mediators significantly reduced mitochondrial respiration compared to uncomplicated pregnancy. 
This corroborates with recent work that showed alterations in mitochondrial morphology in preeclampsia and 
highlighted that miR210 (increased in preeclampsia) is potentially responsible for repression of mitochondrial 
respiration in preeclampsia21.
In the present study we show that mitochondrial-ROS is markedly elevated in HUVEC treated with plasma 
from pregnancies complicated by preeclampsia compared to uncomplicated pregnancies. Increased mROS pro-
duction may be caused by decreased cellular respiration observed in OCR assays as impaired cellular respiration 
can lead to backward flux of electrons in the oxidative phosphorylation chain22. Likewise analysis of the mito-
chondrial placental proteome in preeclampsia reported increased abundance of proteins involved in oxidative 
stress and ROS generation23. Furthermore, recent work in a transgenic murine model overexpressing storkhead 
box 1 (preeclampsia susceptibility gene) showed exaggerated placental mitochondrial activity24.
PGC-1α is a well characterised pleiotropic orchestrator of mitochondrial biogenesis and antioxidant activity25. 
We showed increased PGC-1α protein expression in HUVEC treated with plasma form preeclampsia preg-
nancies. The dynamics of mitochondrial biogenesis and function is a complex system of cellular and molecu-
lar processes. Mitochondrial mass signifies the equilibrium between rates of biogenesis and degradation26. We 
measured mitochondrial mass and found no significant difference in mitochondrial mass in HUVEC treated 
with preeclampsia plasma when compared with plasma from uncomplicated pregnancy. The lack of a change 
in mitochondrial mass could be related to increased rate of degradation; interestingly recent data has shown 
increased autophagy in preeclampsia and in HUVEC’s exposed to oxidative stress27. These results would suggest 
that preeclampsia plasma mediators alter mitochondrial metabolism and provoke mitochondrial dysfunction 
through multiple mechanisms.
Mitochondrial-ROS production is stringently regulated by numerous antioxidant systems in order to main-
tain redox-signalling homeostasis. To determine if these antioxidant pathways were modulated in HUVEC 
treated with plasma from preeclampsia pregnancies, we analysed the expression of both mitochondrial and 
non-mitochondrial antioxidants in the endothelium. Preeclampsia plasma significantly increased mitochondrial 
SOD1, SOD2 and non-mitochondrial HO-1 gene expression respectively. Previous studies have shown elevated 
decidual HO-1 protein expression and increased HO-1 in maternal serum from preeclampsia pregnancies28. 
Previous work has reported reduced SOD1 mRNA and SOD activity in isolated trophoblasts from preeclampsia 
patients29.
Recent reports have demonstrated that mitochondrial DAMPs (mROS and mtDNA) act as ligands for TLR-914. 
Activation of TLR-9 signaling via mtDNA induces a subsequent inflammatory response with the synthesis of 
pro-inflammatory cytokines including TNF-α 14. We showed increased levels of mtDNA in preeclampsia plasma. 
We also reported a significant increase in endothelial TLR-9 gene expression with a consequent increase in 
pro-inflammatory cytokine TNF-α gene expression respectively in HUVEC treated with preeclampsia plasma. 
Figure 7. Effect of MitoTempo on inflammatory and redox signalling markers in HUVEC. HUVEC were 
pre-treated with 5 μ M MitoTempo for 2 hrs prior to exposure to 100 ng/ml LPS for 24 hrs and gene expression 
of inflammatory markers were quantified by real-time PCR. (a) Gene expression of inflammatory markers 
TNF-α and endothelin-1 respectively was determined in LPS-stimulated HUVEC. Cells were pre-treated with 
5 μ M MitoTempo for 2 hrs prior to exposure to 200 μ M H2O2 for 24hrs and gene expression of redox markers 
were quantified by real-time PCR. (b) Gene expression of redox signalling mediators, SOD1, SOD2, HO-1, 
UCP-1and TLR-9 respectively were determined in HUVEC following oxidative stress insult. The amounts of 
amplified products are expressed relative to geometric mean of two internal controls. Data are mean fold change 
compared to control ± SEM. *P < 0.05; **P < 0.01. Data are representative of 3 independent experiments.
www.nature.com/scientificreports/
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TLR-9 expression has been shown to be significantly increased in the placenta in patients with preeclampsia30. 
Furthermore we showed a significant increase in ICAM-1 gene expression (marker of vascular dysfunction) in 
HUVEC treated with preeclampsia plasma. This correlates with previous work, which reported elevated ICAM-1 
expression in preeclampsia31 and in HUVEC’s exposed to pathogenic necrotic trophoblast debris32. Furthermore, 
a recent transcriptomic study in HUVEC exposed to preeclampsia plasma established perturbation in pathways 
mediating endothelial homeostasis33. These findings implicate cross-talk between cellular stressors present in the 
maternal plasma milieu in preeclampsia.
MitoTempo is a mitochondria-targeted superoxide dismutase antioxidant mimetic. We observed that 5 μ M 
MitoTempo rescued cell viability following exposure to oxidative stress (200 μ M H2O2 ). Importantly we showed 
that MitoTempo significantly reduced mROS generation following exposure to plasma from preeclampsia preg-
nancies. Intriguingly, mitochondrial-targeted antioxidant pre-treatment was more effective than general antiox-
idant (NAC) at similar concentrations, highlighting the importance of a direct-targeted therapeutic approach.
In order to specifically characterise the potential signalling pathways mediated by MitoTempo, HUVEC were 
pre-treated with the MitoTempo prior to exposure to two recognised cell stressors (oxidative stress and inflam-
mation) hypothesised to be present as pathogenic mediators in the preeclampsia plasma milieu. We identified 
that MitoTempo exerted an anti-inflammatory response following LPS stimulation with a significant reduction in 
TNF-α gene expression. Interestingly, MitoTempo significantly reduced TLR-9 gene expression only in response 
to H2O2, implicating mROS in provoking inflammatory response in plasma-treated HUVEC. MitoTempo has 
previously been shown to reduce expression of pro-inflammatory cytokines in in vivo models of hypertension34. 
Furthermore MitoTempo significantly normalised UCP-1 gene expression. Uncoupling reduces ROS generation 
by decreasing the electrochemical potential across the inner mitochondrial membrane, reducing the half-life of 
the most reactive steps in the electron transport chain35. Hence our results have identified potential mechanistic 
pathways for mitochondrial scavengers in mediating oxidative damage.
Here we provide evidence for the first time that plasma mediators of preeclampsia dysregulate mitochon-
drial function, generate increased production of deleterious mROS in the endothelium and ultimately provoke 
inflammatory-induced vascular dysfunction. We describe a mechanism for mediating the aberrant production 
of these pathogenic regulators using mitochondrial-targeted antioxidants that directly scavenge mitochon-
drial superoxide production. Our findings delineate that these mitochondrial antioxidants facilitate this out-
come by adapting mitochondrial metabolism. Thus, our study shows that MitoTempo restrains production of 
mROS-mediated deleterious inflammatory cellular signaling pathways and provides evidence that therapeutic 
strategies directly targeting mitochondrial superoxide scavenging should be actively pursued in future therapeu-
tic studies of preeclampsia.
Materials and Methods
Study Subjects. Subjects were recruited from the Screening for Pregnancy Endpoints (SCOPE) study 
Ireland, an international multicentre prospective cohort study of nulliparous singleton pregnancies. Further 
details of this study have been published previously36. Preeclampsia was defined as systolic blood pressure 
≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg on at least 2 occasions 4 hrs apart after 20 weeks’ ges-
tation but before the onset of labor or postpartum, with proteinuria (24 hour urinary protein ≥ 300 mg, or urine 
dipstick protein ≥ 2+ ) or any multisystem complication of preeclampsia. Time-of-disease samples (n = 12) for 
preeclampsia were taken when women had these criteria to diagnose preeclampsia. Control blood samples were 
taken from healthy pregnant women with uncomplicated pregnancies (n = 12) in the SCOPE study and matched 
for age, body mass index (BMI), and gestational age and from non-pregnant women matched for BMI and mater-
nal age (Supplementary Table S1). The SCOPE study was conducted according to the guidelines laid down in the 
Declaration of Helsinki, and all procedures were approved by the Clinical Research Ethics Committee of the Cork 
Teaching (ECM5(10)05/02/08), and all women provided written informed consent.
Sample Collection. Plasma samples were thawed on ice, centrifuged at 3000rpm at 4 °C, and the soluble com-
ponent was removed, the remainder of sample was agitated. An equal volume (20–50ul per sample) was pooled 
with other samples in a single Falcon tube and agitated thoroughly. Aliquots were divided into 30ul volumes for 
storage at − 80 °C. In preliminary experiments, cell viability was determined using a range of plasma concentra-
tions, 3% plasma concentration reduced the cytotoxic effects of plasma while maximizing relative differences 
between subject groups (Supplementary Figure S1). This concentration was used in the remainder of the study.
Cell Culture. Human umbilical vein endothelial cells (HUVEC) (Lonza) were cultured in EBM-2 medium 
supplemented with cell Bullet kit (Lonza). HUVEC were passaged every four days and in all experiments cells at 
passage 4–8 were used.
Cytotoxicity Assay. Cell viability was determined by the colorimetric MTT tetrazolium reduction assay. 
Cells were serum starved for 4hrs prior to incubation with either plasma from preeclampsia patients, MitoTempo 
(Enzo Life Sciences) or N-acetylcysteine (NAC) (Sigma-Aldrich), or Hydrogen peroxide (H2O2)(Sigma-Aldrich) 
or Dimethyl sulfoxide (DMSO) for 24 hrs. In additional experiments, cells were serum starved and pre-treated 
with 5 μ M MitoTempo for 2 hrs prior to exposure to 200 μ M H2O2 for 24 hrs. Following treatment, 10 ul of MTT 
(final concentration 5 mg/ml) was added to each well and absorbance read at 570 nm, with 630 nm as a reference. 
Cell viability % = absorbance of each treated cells/absorbance of control (DMSO) treated cells x100.
Isolation of RNA and Real-time PCR analysis. HUVEC were serum starved for 4 hrs prior to treatment 
with either 3% plasma, 5 μ M MitoTempo, 5 uM NAC, 200 μ M H2O2, 100 ng/ml LPS or DMSO control for 24 hrs. 
For MitoTempo antioxidant experiments, cells were serum starved for 4 hrs, pre-treated with 5 μ M MitoTempo 
for 2 hrs and then treated with 3% plasma, 200 μ M H2O2, or 100 ng/ml LPS for 24 hrs. RNA was extracted using 
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the RNeasy mini-kit (Qiagen). Superoxide dismutase 1 (SOD1), SOD2, uncoupling protein-1 (UCP-1), heme 
oxygenase-1 (HO-1), toll-like receptor 9 (TLR-9), tumour necrosis factor-α (TNF-α ) and intracellular adhesion 
molecule-1 (ICAM-1) gene expression was quantified by Real-Time PCR using the StepONE Plus Detection sys-
tem. Taqman assays (Applied BioSystems) and Sybr Green primers (Supplementary Table S2 online) were used 
for quantification. The amounts of target gene, normalized to geometric mean of two internal controls (18S and 
Tata Binding Protein) were determined using the 2−ΔΔCT.
mtDNA Quantification. DNA was extracted from 200 μ l of plasma from both preeclampsia (n = 12) and 
uncomplicated pregnancies (n = 12) respectively with QIAmp DNA mini kit (Qiagen) according to manufactur-
er’s instructions. Real-Time PCR was performed with 10 ng total DNA using the StepOne Plus Detection system. 
Mitochondrial DNA primers (hMitoF5, hMitoR5) and β 2M nuclear genome primers (β 2MF2, β 2MR2) were used 
for quantitation and are provided in Supplementary Table S2 online. Relative quantification of mitochondrial 
DNA (mtDNA) over nuclear DNA levels were determined using the using the 2−ΔΔCT method.
Immunofluoresence. HUVEC were serum starved for 4 hrs and treated with 3% plasma for 24 hrs. Cells 
were initially fixed in 3% paraformaldehyde for 15 mins, prior to incubation in 0.2% Triton X-100 (Sigma-Aldrich) 
for 5 mins. Cells were blocked with 5% Bovine Serum Albumin (BSA) at room temperature for 30 mins prior to 
incubation with PGC-1α (1:200) (Novus Biologicals) overnight at 4 °C. Cells were then incubated with Alexa 
Fluor 488 goat anti-rabbit fluorescent secondary antibody (Invitrogen) at a 1:200 dilution. Cells were counter-
stained with 4,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (10 μ g/ml) to identify nuclei. Cells were 
visualized by fluorescent microscopy (Zeiss AxioImager M2). Mean fluorescent intensity was analyzed using 
Image J software in at least 10 random fields of view and compared to DMSO controls.
Determination of mitochondrial mass. Mitochondrial mass was measured using MitoID Green fluo-
rescent marker (Enzo Life Sciences) according to manufacturer’s instructions. MitoID Green is a cell-permeable 
small organic probe that spontaneously localizes to mitochondria regardless of their membrane potential. Briefly, 
cells were serum starved for 1hour and incubated with 3% plasma for 4hrs. Media was removed and cells were 
loaded with 500 μ l 1X Assay buffer containing 0.5 μ l MitoID Green Reagent and 0.5 μ l Hoechst 33342 Nuclear 
Stain for 30 mins at 37 °C. Cells were then washed with PBS and fixed in 3% paraformaldehyde for 15 mins, prior 
to mounting. Mean fluorescent intensity was analyzed using Image J software in at least 10 random fields of view 
and compared to non-pregnant controls.
Detection of mitochondrial superoxide by fluorescent microscopy. Intramitochondrial superox-
ide production was measured in treated HUVEC using the MitoSOX Red fluorescent reagent (Invitrogen). This 
fluorogenic dye selectively enters mitochondria within living cells where it is oxidized by superoxide anions. This 
oxidation reaction then emits a red fluorescence when bound to mitochondrial DNA. Cells were serum starved 
for 1hour and incubated with 3% plasma for 4hrs. Alternatively, cells were serum starved for 1hour, pre-treated 
with 5 μ M Mito-Tempo, 5 uM N-acetylcysteine (NAC), or DMSO control for 2 hrs and incubated with 3% plasma 
for 4 hrs. Media was removed and cells were loaded with 0.5 uM MitoSox Red for 30 mins at 37 °C. Cells were then 
fixed and permeabilized prior to nuclear localization with DAPI. Mean fluorescent intensity was analyzed using 
Image J software in at least 10 random fields of view and compared to DMSO controls.
Measurement of Mitochondrial O2 consumption. MitoXpress® Xtra–Oxygen Consumption Assay 
(Luxel Biosciences) was used for the direct, real-time analysis of cellular respiration and mitochondrial function. 
MitoXpress® Xtra is quenched by O2 through molecular collision, and thus the amount of fluorescence signal is 
inversely proportional to the amount of extracellular O2 in the sample. HUVEC were serum starved for 1 hour 
and incubated with 3% plasma for 4 hrs. After incubation cells were washed with clear respiration media. The 
MitoXpress-Xtra-HS probe was added to cells in accordance with manufacturer’s instructions. Oxygen consump-
tion was measured using time-resolved fluorescence (TR-F) with a dual delay of 30 μ s and 70 μ s using a VarioSkan 
fluorescence plate reader (Thermo-Scientific). Rate of oxygen consumption was determined from the slope of 
fluorescence vs. time for each sample using relative fluorescence units/hour.
Statistical Analysis. Data are shown as mean ± SEM, or fold change relative to vehicle control of at least 10 
independent experiments. Mann Whitney U test or analyses of variance (ANOVA) were used where appropri-
ate to determine statistical significance between groups in in vitro studies unless otherwise specified. Values of 
**P ≤ 0.01 and *P ≤ 0.05 were considered significant
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